A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : VGS / viridans group streptococci

[Related PubMed/MEDLINE]
Total Number of Papers: 121
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   VGS  (>> Co-occurring Abbreviation)
Long Form:   viridans group streptococci
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 Antimicrobial Activity of Telavancin Tested In Vitro Against a Global Collection of Gram-Positive Pathogens, Including Multidrug-Resistant Isolates (2015-2017). BHS, CLSI, MRSA
2019 Activity of tedizolid against gram-positive clinical isolates causing infections in Europe and surrounding areas (2014-2015). ---
2019 An Analysis of Resistance Patterns of Oral Streptococci Obtained from Orofacial Infections Against Beta-lactams, Clindamycin and Vancomycin over 2014-2018. AST
2019 Antimicrobial activity of dalbavancin tested against Gram-positive organisms isolated from patients with infective endocarditis in US and European medical centres. ---
2019 Be careful about MICs to amoxicillin for patients with Streptococci-related infective endocarditis. BGS, CI, IE, IQR, MICs
2019 Cumulative incidence and mortality of infective endocarditis in Siriraj hospital-Thailand: a 10-year retrospective study. DM, DRIE, ESRD, IE, MSSA, NVE, PVE
2019 Daptomycin Dose-Ranging Evaluation with Single-Dose versus Multidose Ceftriaxone Combinations against Streptococcus mitis/oralis in an Ex Vivo Simulated Endocarditis Vegetation Model. CRO, DAP, DAP-R, DAP-S, IE, PK/PD, SEVs
2019 Differentiation between Streptococcus pneumoniae and other viridans group streptococci by matrix-assisted laser desorption/ionization time of flight mass spectrometry. CI, MALDI-TOF MS
2019 Endocarditis Caused by Highly Penicillin-Resistant Viridans Group Streptococci: Still Room for Vancomycin-Based Regimens. EE, HLDR, IE, Penr
10  2019 Epidemiological and clinical characteristics of Streptococcus tigurinus endocarditis. ---
11  2019 Mutations in cdsA and pgsA Correlate with Daptomycin Resistance in Streptococcus mitis and S. oralis. DAP
12  2019 Variants of the bile: solubility test to differentiate Streptococcus pneumoniae from other viridans group streptococci. ---
13  2019 [Identification and antibiotic susceptibility of viridans group streptococci isolates recovered from patients hospitalized at a teaching hospital in Buenos Aires City]. ---
14  2018 Activity of dalbavancin and comparator agents against Gram-positive cocci from clinical infections in the USA and Europe 2015-16. ABSSSIs, BHS, GPC
15  2018 Acute Streptococcus mitis Sacroiliitis in a Teenager with Unclear Source of Bacteremia: A Case Report and Literature Review. ---
16  2018 Assessment of periodontitis and its role in viridans streptococcal bacteremia and infective endocarditis. IE
17  2018 Dalbavancin in-vitro activity obtained against Gram-positive clinical isolates causing bone and joint infections in US and European hospitals (2011-2016). BHS, BJI, CoNS, MIC
18  2018 Epidemiology, Clinical Features, and Outcome of Infective Endocarditis due to Abiotrophia Species and Granulicatella Species: Report of 76 Cases, 2000-2015. ABI, GRA, HACEK, IE
19  2018 Profile of Infective Endocarditis: At a Tertiary Care Referral Centre. IE, RHD
20  2018 Rare but Not Infrequent: Infective Endocarditis Caused by Abiotrophia defectiva. NVS
21  2018 Risk Factors for Viridans Group Streptococcal Bacteremia in Neutropenic and Non-neutropenic Patients: A Single Center Case-Case-Control Study. CI, OR
22  2018 Surgically Treated Community-Acquired Brain Abscess: Bacteriological Analysis Based on Predisposing Infections. ---
23  2018 The clinical impact of patients with bloodstream infection with different groups of Viridans group streptococci by using matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS). MALDI-TOF MS
24  2017 Activity of dalbavancin tested against Gram-positive clinical isolates causing skin and skin-structure infections in paediatric patients from US hospitals (2014-2015). BHS, CoNS, MRSA, SSSIs
25  2017 Impact of AHA's 2007 guideline change on incidence of infective endocarditis in infants and children. AHA, IE, NIS
26  2017 Prevalence of macrolide-lincosamide resistance and multidrug resistance phenotypes in streptococcal isolates causing infections in European hospitals: Evaluation of the in vitro activity of oritavancin and comparator agents. BHS, MDR, MIC
27  2017 [Comparison of MALDI-TOF and 16S rRNA methods in identification of viridans group streptococci]. ---
28  2016 A comparison of discharge strategies after chemotherapy completion in pediatric patients with acute myeloid leukemia: a report from the Children's Oncology Group. AML, aRR
29  2016 Antibodies Targeting Hsa and PadA Prevent Platelet Aggregation and Protect Rats against Experimental Endocarditis Induced by Streptococcus gordonii. IE
30  2016 Antimicrobial susceptibility against penicillin, ampicillin and vancomycin of viridans group Streptococcus in oral microbiota of patients at risk of infective endocarditis. IE
31  2016 Association of oral flora with orbital complications of acute sinusitis. ---
32  2016 Ceftaroline activity tested against viridans group streptococci from US hospitals. MALDI-TOF
33  2016 Complete Genome Sequence of Streptococcus mitis Strain SVGS_061 Isolated from a Neutropenic Patient with Viridans Group Streptococcal Shock Syndrome. ---
34  2016 Effect of Periodontal Therapy With Amoxicillin-Metronidazole on Pharyngeal Carriage of Penicillin- and Erythromycin-Resistant Viridans Streptococci. MIC
35  2016 In vitro activity of dalbavancin against multidrug-resistant Staphylococcus aureus and streptococci from patients with documented infections in Europe and surrounding regions (2011-2013). FDA, MDR, MRSA
36  2016 In vitro activity of dalbavancin and five comparator agents against common and uncommon Gram-positive organisms isolated from cancer patients. MRSA, TMP/SMX
37  2016 Pronounced heterogeneity observed in high-level daptomycin-resistant viridans group streptococci. HLDR
38  2016 Rare and unusual isolates of viridans streptococci from the human oral cavity. ---
39  2016 The causative agents in infective endocarditis: a systematic review comprising 33,214 cases. CoNS, IE
40  2016 Using Matrix-Assisted Laser Desorption Ionization-Time of Flight (MALDI-TOF) Complemented with Selected 16S rRNA and gyrB Genes Sequencing to Practically Identify Clinical Important Viridans Group Streptococci (VGS). MALDI-TOF
41  2016 Viridans Group Streptococcal Infections in Children After Chemotherapy or Stem Cell Transplantation: A 10-year Review From a Tertiary Pediatric Hospital. VGSB
42  2015 Characterization of high-level daptomycin resistance in Viridans group Streptococci developed upon in vitro exposure to daptomycin. HLDR
43  2015 Clinical Significance and Characterization of Streptococcus tigurinus Isolates in an Adult Population. MALDI-TOF MS
44  2015 Comparison of antibiotic susceptibility in viridans group streptococci in low and high antibiotic-prescribing General Practices. GP
45  2015 Febrile neutropenia in children treated for malignancy. BSI, CDR, FN, IFI, MDR
46  2015 Incidence of Infective Endocarditis Due to Viridans Group Streptococci Before and After the 2007 American Heart Association's Prevention Guidelines: An Extended Evaluation of the Olmsted County, Minnesota, Population and Nationwide Inpatient Sample. AHA, IE
47  2015 Species-specific difference in antimicrobial susceptibility among viridans group streptococci. ---
48  2015 Surrogate analysis of vancomycin to predict susceptible categorization of dalbavancin. ABSSSIs, BHS, CA, DAL, USA, VAN
49  2015 Use of in vitro vancomycin testing results to predict susceptibility to oritavancin, a new long-acting lipoglycopeptide. BHS, CoNS, ENT
50  2015 Viridans Group Streptococci clinical isolates: MALDI-TOF mass spectrometry versus gene sequence-based identification. MALDI-TOF MS
51  2014 Development and validation of a clinical model to predict the presence of beta-lactam resistance in viridans group streptococci causing bacteremia in neutropenic cancer patients. BSI, MIC
52  2014 Effective oral health in infective endocarditis: efficacy of high-street mouthwashes against the viridans group streptococci. IE, NCTC
53  2014 Genetic determinants and elements associated with antibiotic resistance in viridans group streptococci. ---
54  2014 GyrB polymorphisms accurately assign invasive viridans group streptococcal species. gyrB, MLSA
55  2014 Identification and characterization of catheter-related bloodstream infections due to viridans group streptococci in patients with cancer. BSI
56  2014 In vitro activity of telavancin compared with vancomycin and linezolid against Gram-positive organisms isolated from cancer patients. CoNS, MICs, MR, MRSA, MS, MSSA
57  2014 Predictors and outcomes of viridans group streptococcal infections in pediatric acute myeloid leukemia: from the Canadian infections in AML research group. AML, CI, OR, VSSS
58  2014 Species-level assessment of the molecular basis of fluoroquinolone resistance among viridans group streptococci causing bacteraemia in cancer patients. MLSA, QRDRs
59  2014 Streptococcus mitis strains causing severe clinical disease in cancer patients. ---
60  2014 The Role of Corticosteroids in Adult Respiratory Distress Syndrome caused by Viridans Group Streptococci Bacteremia in Neutropenic Patients. ARDS
61  2013 Comparative Genomic Analyses of Streptococcus pseudopneumoniae Provide Insight into Virulence and Commensalism Dynamics. SPPN
62  2013 Early in vitro and in vivo development of high-level daptomycin resistance is common in mitis group Streptococci after exposure to daptomycin. HLDR
63  2013 High frequency of streptococcal bacteraemia during childhood AML therapy irrespective of dose of cytarabine. NOPHO
64  2013 Population structure and characterization of viridans group streptococci (VGS) isolated from the upper respiratory tract of patients in the community. AR
65  2013 Spectrum and potency of ceftaroline tested against leading pathogens causing skin and soft-tissue infections in Europe (2010). AWARE, cSSTIs, MRSA, MSSA
66  2013 Spectrum of gram-positive bacteraemia and in vitro activities of daptomycin, linezolid and vancomycin against organisms isolated from cancer patients. CoNS
67  2013 Update of dalbavancin spectrum and potency in the USA: report from the SENTRY Antimicrobial Surveillance Program (2011). betaHS, DAL, DAP, SA, VAN
68  2013 Value of matrix-assisted laser desorption ionization-time of flight for routine identification of viridans group streptococci causing bloodstream infections. MALDI-TOF
69  2012 Incidence of infective endocarditis caused by viridans group streptococci before and after publication of the 2007 American Heart Association's endocarditis prevention guidelines. IE
70  2012 Phenotypic and genotypic characterization of Thai oral streptococci, lactobacilli and pediococci. Group I
71  2011 Bacterial contamination of Saudi "one" Riyal paper notes. ---
72  2011 Comparasion of five gene loci (rnpB, 16S rRNA, 16S-23S rRNA, sodA and dnaJ) to aid the molecular identification of viridans-group streptococci and pneumococci. ---
73  2011 Comparison of minimum inhibitory concentration by broth microdilution testing versus standard disc diffusion testing in the detection of penicillin, erythromycin and ciprofloxacin resistance in viridans group streptococci. ---
74  2011 Efficacy and safety of outpatient parenteral antibiotic therapy for infective endocarditis: a ten-year prospective study. IE, OPAT, S. aureus, S. bovis
75  2011 Evaluation of the MicroScan MICroSTREP plus antimicrobial panel for testing beta-hemolytic streptococci and viridans group streptococci. BHS, CA, MICs
76  2011 Identification of clinically relevant viridans group streptococci by phenotypic and genotypic analysis. MLSA, RFLP
77  2011 Misidentification of alpha-hemolytic streptococci by routine tests in clinical practice. DBP, MALDI-TOF MS, MLSA
78  2011 Molecular characterisation of the quinolone resistance-determining region (QRDR) of the parC gene locus in viridans-group streptococci. MIC, QRDR
79  2011 Molecular characterization and phylogenetic analysis of quinolone resistance-determining regions (QRDRs) of gyrA, gyrB, parC and parE gene loci in viridans group streptococci isolated from adult patients with cystic fibrosis. CF, QRDRs
80  2011 Population structure and characterization of viridans group streptococci (VGS) including Streptococcus pneumoniae isolated from adult patients with cystic fibrosis (CF). CF, MIC
81  2011 Prevalence of clustered regulatory interspaced short palindromic repeat (CRISPR)-like sequences in mitis-group streptococci. Cas, CRISPR, CRISPRs, PCR
82  2011 The role of streptococcal plasmin(ogen) binding in infective endocarditis. ---
83  2011 Whole-genome sequence of Streptococcus pseudopneumoniae isolate IS7493. ---
84  2010 Antibiotic susceptibility and resistance of the odontogenic microbiological spectrum and its clinical impact on severe deep space head and neck infections. ---
85  2010 It's not easy being green: the viridans group streptococci, with a focus on pediatric clinical manifestations. MALDI-TOF, SAG
86  2010 [Classical and new approaches in laboratory diagnosis of viridans streptococci]. ---
87  2009 Denaturing gradient gel electrophoresis of PCR-amplified gki genes: a new technique for tracking streptococci. DGGE, ERIC-PCR, gki
88  2009 In vitro inferiority of ceftazidime compared with other beta-lactams for viridans group Streptococcus bacteremia in pediatric oncology patients: implications for antibiotic choices. ---
89  2009 Molecular characterization of macrolide resistance determinants [erm(B) and mef(A)] in Streptococcus pneumoniae and viridans group streptococci (VGS) isolated from adult patients with cystic fibrosis (CF). CF
90  2009 [Enterococcal endocarditis: a multicenter study of 76 cases]. IE, LSIE
91  2008 Identification of species of viridans group streptococci in clinical blood culture isolates by sequence analysis of the RNase P RNA gene, rnpB. ---
92  2008 Pediatric infective endocarditis: Has Staphylococcus aureus overtaken viridans group streptococci as the predominant etiological agent? IE
93  2008 Phylogenetic analysis of viridans group streptococci causing endocarditis. ---
94  2007 Antimicrobial susceptibility patterns and macrolide resistance genes of beta-hemolytic viridans group streptococci in a tertiary Korean hospital. MICs, PCR
95  2007 Effects of tigecycline, linezolid and vancomycin on biofilms of viridans streptococci isolates from patients with endocarditis. MIC, OD, ODR
96  2007 In vitro susceptibility of viridans group streptococci isolated from blood in southwest Finland in 1993-2004. ---
97  2007 Infections with viridans group streptococci in children with cancer. ---
98  2007 Multicenter evaluation of the BD Phoenix Automated Microbiology System for antimicrobial susceptibility testing of Streptococcus species. AST, CA, CLI, CTR, CTX, ERY, GBS, PEN, TET, VMEs
99  2007 [Phenotypes and genetic mechanisms of resistance to macrolides and lincosamides in viridans group streptococci]. ---
100  2006 Low incidence of sepsis due to viridans streptococci in a ten-year retrospective study of pediatric acute myeloid leukemia. AML, CDI, FUO, ICs, MDI